Ahead of March 24's World TB Day, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has confirmed the biopharma industry's commitment to the World Health Organization (WHO) drive to eradicate tuberculosis and its campaign, “Wanted: Leaders for a TB-free world”, focusing on building commitment at all levels of the community. An IFPMA press releases notes that the biopharmaceutical industry is contributing to the TB challenge with R&D measures to improve access to treatments and to find more effective, safer, all-oral regimens to treat all forms of TB, and new vaccines for adolescents and adults. There are now over 60 R&D projects for TB medicines and vaccines in the pipeline, including seven products in phase III clinical trials. Recent breakthroughs made by Johnson & Johnson and Otsuka (bedaquiline and delamanid) for the treatment of MDR-TB are illustrative of new approaches being taken by biopharma companies to make broadening sustainable and responsible access a priority. "2018 is a critical year for the global TB community", writes IFPMA, "culminating with the first ever UN High-Level Meeting on TB on September 26, 2018".
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.